BMI1, ALDH1A1, and CD133 transcripts connect epithelial-mesenchymal transition to cancer stem cells in lung carcinoma

48Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Epithelial-mesenchymal transition (EMT) is the underlying mechanism of tumor invasion and metastasis. Evidences from lung cancer cellular models show EMT can trigger conversion to a cancer stem cell (CSC) phenotype. In this study, we assessed mRNA expression levels of EMT-inducing transcription factors (BMI1, TWIST1), CSC (CD133, ALDH1A1), and epithelial (EpCAM) markers in primary tumor and whole blood samples obtained from 57 patients with operable non-small-cell lung cancer (NSCLC) as well as in circulating tumor cells (CTCs) of 13 patients with metastatic disease; then possible associations between marker expressions were evaluated. In primary tumors as well as in whole blood, correlations between BMI1 and ALDH1A1 and between BMI1 and CD133 mRNA expressions were identified. No correlations between TWIST1 and CSC markers were observed. BMI1 mRNA expression in tumors positively correlated with BMI1 mRNA expression in blood. The immunohistochemical analysis confirmed coexpression of BMI1 and CSC markers in tumors. Gene expression profiling in CTCs revealed upregulated expression of EMT/CSC markers in CTCs. Our results suggest CSCs are present in both, tumor tissue and blood of NSCLC patients, whereas Bmi1 may play an important role in initiation and maintenance of CSCs and might be involved in the blood-borne dissemination of NSCLC.

Figures

  • Table 1: Clinical characteristics of 57 operable and 13 advanced NSCLC patients.
  • Figure 1: mRNA expression levels of EMT (BMI1, TWIST1), CSC (CD133, ALDH1A1), and epithelial (EpCAM) markers in primary tumors and whole blood samples of 57 NSCLC patients. Data are shown as scattered plot for all measured values with line in the middle representing the median.
  • Figure 2: Association between EMT in CSC marker expression in primary-tumors of 57 NSCLC patients. (a) Linear regression results between BMI1, ALDH1A1, and CD133 mRNA expression. (b) Correlation of the IHC grading of BMI1, ALDH1A1, and CD133 protein expression. (c) Representative results of IHC stainings for BMI1, ALDH1A1, and CD133 at different staining intensities (top, high positive; bottom, low positive/negative).
  • Figure 3: Expression levels of CSC (CD133, ALDH1A1) and EMT (BMI1, TWIST1) in EpCAM-positive CTCs of 10 patients with metastatic NSCLC. Dashed line represents relative mRNA level in PBMNCs. ALDH1A1 and BMI1 transcripts were detected in 10/10 patients whereas CD133 and TWIST1 transcripts were detected in 5/10 and 4/10 patients, respectively. Data are shown as scattered plot for all measured values with line in the middle representing the median mRNA expression level of marker in CTCs.

References Powered by Scopus

Get full text

This article is free to access.

Global cancer statistics

31580Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Koren, A., Rijavec, M., Kern, I., Sodja, E., Korosec, P., & Cufer, T. (2016). BMI1, ALDH1A1, and CD133 transcripts connect epithelial-mesenchymal transition to cancer stem cells in lung carcinoma. Stem Cells International, 2016. https://doi.org/10.1155/2016/9714315

Readers over time

‘16‘17‘18‘19‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

68%

Researcher 6

24%

Professor / Associate Prof. 1

4%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 10

40%

Medicine and Dentistry 8

32%

Agricultural and Biological Sciences 4

16%

Pharmacology, Toxicology and Pharmaceut... 3

12%

Save time finding and organizing research with Mendeley

Sign up for free
0